deltatrials
Completed PHASE2 INTERVENTIONAL 4-arm NCT05233774

Lomecel-B Effects on Alzheimer's Disease (CLEARMIND)

Lomecel-B Effects on Alzheimer's Disease: A Randomized, Double-Blinded, Placebo-Controlled Phase 2a Trial

Sponsor: Longeveron Inc.

Conditions Mild Alzheimer's Disease
Interventions Allogeneic MSC Placebo
Updated 7 times since 2022 Last updated: Feb 16, 2024 Started: Dec 28, 2021 Primary completion: Sep 29, 2023 Completion: Sep 29, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Mild Alzheimer's Disease, this trial is completed. The trial is conducted by Longeveron Inc. and has accumulated 7 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Mar 2022 – ~Apr 2022 · 31 days · monthly snapshotRecruiting~Apr 2022 – ~Sep 2022 · 5 months · monthly snapshotRecruiting~Sep 2022 – ~May 2023 · 8 months · monthly snapshotRecruiting~May 2023 – ~Mar 2024 · 10 months · monthly snapshotActive Not Recruiting~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 22 months · monthly snapshotCompleted

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Mar 2024 — Jul 2024 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  4. May 2023 — Mar 2024 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  5. Sep 2022 — May 2023 [monthly]

    Recruiting PHASE2

▶ Show 2 earlier versions

  1. Apr 2022 — Sep 2022 [monthly]

    Recruiting PHASE2

  2. Mar 2022 — Apr 2022 [monthly]

    Recruiting PHASE2

    First recorded

Dec 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Longeveron Inc.
  • bioRASI, LLC
Data source: Longeveron Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations